PEGFILGRASTIM VERSUS FILGRASTIM IN THE MANAGEMENT OF POST-CHEMOTHERAPY NEUTROPENIA IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA IN TREATMENT WITH BVD (BENDAMUSTINE BORTEZOMIB-DEXAMETHASONE)

被引：0
|
作者：
Cerchione, C. [1 ]
Nappi, D. [1 ]
Salvatore, D. [1 ]
Migliaccio, I. [1 ]
Pane, F. [1 ]
Catalano, L. [1 ]
机构：
[1] Au Federico Ii, Hematol Ematol & Trapianto, Naples, Italy
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E1330
引用
收藏
页码：550 / 551
页数：2
相关论文
共 50 条
  • [41] Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma
    Ludwig, Heinz
    Kasparu, Hedwig
    Leitgeb, Clemens
    Rauch, Elisabeth
    Linkesch, Werner
    Zojer, Niklas
    Greil, Richard
    Seebacher, Adelheid
    Pour, Ludek
    Weissmann, Adalbert
    Adam, Zdenek
    BLOOD, 2014, 123 (07) : 985 - 991
  • [42] Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study
    M Offidani
    L Corvatta
    L Maracci
    A M Liberati
    S Ballanti
    I Attolico
    P Caraffa
    F Alesiani
    T Caravita di Toritto
    S Gentili
    P Tosi
    M Brunori
    D Derudas
    A Ledda
    A Gozzetti
    C Cellini
    L Malerba
    A Mele
    A Andriani
    S Galimberti
    P Mondello
    S Pulini
    U Coppetelli
    P Fraticelli
    A Olivieri
    P Leoni
    Blood Cancer Journal, 2013, 3 : e162 - e162
  • [43] Indirect Treatment Comparisons of Daratumumab, Pomalidomide, and Dexamethasone Versus Daratumumab, Bortezomib, and Dexamethasone or Bortezomib and Dexamethasone in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma
    He, Jianming
    Berringer, Heather
    Heeg, Bart
    Kampfenkel, Tobias
    Dwarakanathan, Harikumaran R.
    Johnston, Stephen
    Mendes, Joao
    Lam, Annette
    Bathija, Sacheeta
    Mackay, Eric
    BLOOD, 2021, 138
  • [44] Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) Patients: An Update of Overall Survival in Castor
    Lentzsch, Suzanne
    Quach, Hang
    Chanan-Khan, Asher A.
    Horvath, Noemi
    Capra, Marcelo
    Ovilla, Roberto
    Jo, Jae-Cheol
    Shin, Ho-Jin
    Thiyagarajah, Piruntha
    Amin, Himal
    Casneuf, Tineke
    Sonneveld, Pieter
    Schecter, Jordan
    Hungria, Vania T. M.
    BLOOD, 2017, 130
  • [45] Pegfilgrastim Versus Filgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Treatment with Pomalidomide-Dexamethasone
    Cerchione, Claudio
    Nappi, Davide
    Musuraca, Gerardo
    Ronconi, Sonia
    Cangini, Delia
    Ceccolini, Michela
    Martinelli, Giovanni
    BLOOD, 2022, 140 : 13248 - 13249
  • [46] Pegfilgrastim Versus Filgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Treatment with Pomalidomide-Dexamethasone
    Cerchione, Claudio
    Catalano, Lucio
    Martinelli, Giovanni
    AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 : S4 - S5
  • [47] Bendamustine, bortezomib, and dexamethasone (BVD) in elderly patients with relapsed/refractory multiple myeloma (RRMM): The Intergroupe Francophone du Myelome (IFM) 2009-01 protocol.
    Rodon, Philippe
    Hulin, Cyrille
    Pegourie, Brigitte
    Tiab, Mourad
    Anglaret, Bruno
    Benboubker, Lotfi
    Jardel, Henry
    Decaux, Olivier
    Kolb, Brigitte
    Roussel, Murielle
    Garderet, Laurent
    Leleu, Xavier
    Fitoussi, Olivier
    Chaleteix, Carine
    Casassus, Philippe
    Lenain, Pascal
    Moreau, Philippe
    Petillon, Marie-Odile
    Mathiot, Claire
    Avet-Loiseau, Herve
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [48] Pegfilgrastim Versus Filgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Treatment With Pomalidomide-Dexamethasone
    Cerchione, Claudio
    Martinelli, Giovanni
    Nappi, Davide
    Pareto, Anna Emanuele
    Di Perna, Maria
    Ronconi, Sonia
    Pane, Fabrizio
    Catalano, Lucio
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E358 - E358
  • [49] PEGFILGRASTIM VERSUS FILGRASTIM IN THE SUPPORTIVE CARE OF HEAVILY PRETREATED MULTIPLE MYELOMA IN TREATMENT WITH POMALIDOMIDE-DEXAMETHASONE
    Cerchione, C.
    Catalano, L.
    Nappi, D.
    Pareto, A. E.
    Musuraca, G.
    Lucchesi, A.
    Ronconi, S.
    Ceccolini, M.
    Cangini, D.
    Giannini, M. B.
    Di Battista, V.
    Simonetti, G.
    Ferrari, A.
    Bochicchio, M. T.
    di Rora, A. Ghelli Luserna
    Ghetti, M.
    Napolitano, R.
    Fontana, M. C.
    Padella, A.
    Pane, F.
    Martinelli, G.
    HAEMATOLOGICA, 2020, 105 : S45 - S45
  • [50] Pegfilgrastim Versus Filgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Treatment With Pomalidomide-Dexamethasone
    Cerchione, Claudio
    Catalano, Lucio
    Nappi, Davide
    Ronconi, Sonia
    Cangini, Delia
    Ceccolini, Michela
    Musuraca, Gerardo
    Marchesini, Matteo
    Pane, Fabrizio
    Martinelli, Giovanni
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S427 - S427
12345